69.92 % to Target, Cantor Fitzgerald Reaffirms ‘”Buy”’ Rating on CytomX Therapeutics Inc (CTMX) Shares Today

May 17, 2018 - By Jason Grubb

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Logo

CytomX Therapeutics Inc (CTMX) Rating Reaffirmed

Cantor Fitzgerald now has a $40.0000 PT on shares of CytomX Therapeutics Inc (CTMX). The PT suggests a potential upside of 69.92 % from the last close price of CytomX Therapeutics Inc (CTMX). This rating was revealed in a research report on 16 May.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Ratings Coverage

Among 2 analysts covering CytomX Therapeutics (CTMX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytomX Therapeutics has $40 highest and $40 lowest target. $40’s average target is 69.92% above currents $23.54 stock price. CytomX Therapeutics had 2 analyst reports since January 5, 2018 according to SRatingsIntel. On Thursday, March 8 the stock rating was maintained by Bank of America with “Buy”.

The stock decreased 3.29% or $0.8 during the last trading session, reaching $23.54. About 533,002 shares traded or 40.80% up from the average. CytomX Therapeutics, Inc. (CTMX) has risen 66.04% since May 18, 2017 and is uptrending. It has outperformed by 54.49% the S&P500.

Analysts await CytomX Therapeutics, Inc. (NASDAQ:CTMX) to report earnings on August, 6. They expect $-0.36 EPS, up 47.83 % or $0.33 from last year’s $-0.69 per share. After $-0.40 actual EPS reported by CytomX Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -10.00 % EPS growth.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical firm in the United States. The company has market cap of $917.06 million. The firm develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. It currently has negative earnings. The Company’s other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188.

More notable recent CytomX Therapeutics, Inc. (NASDAQ:CTMX) news were published by: Globenewswire.com which released: “CytomX Therapeutics Announces First Quarter 2018 Financial Results” on May 09, 2018, also Globenewswire.com with their article: “CytomX Therapeutics to Announce First Quarter 2018 Financial Results” published on May 01, 2018, Benzinga.com published: “22 Stocks Moving In Thursday’s Pre-Market Session” on May 17, 2018. More interesting news about CytomX Therapeutics, Inc. (NASDAQ:CTMX) were released by: Seekingalpha.com and their article: “CytomX up 6% premarket on CX-072 data” published on May 17, 2018 as well as Nasdaq.com‘s news article titled: “CytomX to Present at the Bank of America Merrill Lynch 2018 Health Care Conference” with publication date: May 07, 2018.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: